Infections caused by respiratory syncytial viruses – epidemiology, clinical picture, diagnosis, prevention and treatment options

1. Buchholz UJ, Anderson LJ, Collins PL, Mejias A. Respiratory syncytial virus and metapneumovirus. In: Howley PM, Knipe DM (eds.). Field’s Virology - Volume 3: RNA viruses. Philadelphia: Wolters Kluwer 2023: 267–317.

2. Borchers AT , Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus-- a comprehensive review. Clin Rev Allergy Immunol 2013; 45: 331–379.

3. Bohmwald K, et al. Contribution of Cytokines to Tissue Damage During Human Respiratory Syncytial Virus Infection. Front Immunol 2019; 10: 452.

4. Bergeron HC, Tripp RA. RSV Replication, Transmission, and Disease Are Influenced by the RSV G Protein. Viruses 2022; 14.

5. S traňák Z. Imunoprofylaxe závažných forem RSV infekce neovlivňuje očkování u dětí – nová indikační kritéria. Pediatr praxi 2015; 16: 247–250.

6. M unywoki PK, et al. Influence of age, severity of infection, and co-infection on the duration of respiratory syncytial virus (RSV) shedding. Epidemiol Inf 2015; 143: 804–812.

7. K ombe IK, Munywoki PK, Baguelin M, et al. Model-based estimates of transmission of respiratory syncytial virus within households. Epidemics 2019; 27: 1–11.

8. Janet S, Broad J, Snape MD. Respiratory syncytial virus seasonality and its implications on prevention strategies. Human Vaccines Immunother 2018; 14: 234–244.

9. O bando-Pacheco P, et al. Respiratory Syncytial Virus Seasonality: A Global Overview. J Inf Dis 2018; 217: 1356–1364.

10. H artert TV, Ortiz JR. Need for improved global measurement of early childhood respiratory syncytial virus disease. Lancet 2022; 399: 1993–1995.

11. P ratt MTG, et al. Prevalence of respiratory viruses in community-acquired pneumonia in children: a systematic review and meta-analysis. Lancet 2022; 6: 555–570.

12. Vazquez Y, et al. Cytokines in the Respiratory Airway as Biomarkers of Severity and Prognosis for Respiratory Syncytial Virus Infection: An Update. Front Immunol 2019; 10: 1154.

13. M anti S, Piedimonte G. An overview on the RSV-mediated mechanisms in the onset of non-allergic asthma. Front Pediatr 2022; 10: 998296.

14. Wennergren G, Kristjansson S. Relationship between respiratory syncytial virus bronchiolitis and future obstructive airway diseases. Eur Resp J 2001; 18: 1044–1058.

15. H on KL, Leung AKC, Wong AHC, et al. Respiratory Syncytial Virus is the Most Common Causative Agent of Viral Bronchiolitis in Young Children: An Updated Review. Curr Ped Rev 2023; 19: 139–149.

16. R uiz S, Calvo C, Pozo F, et al. Lung function, allergic sensitization and asthma in school-aged children after viral-coinfection bronchiolitis. Sci Reports 2022; 12: 7552.

17. L iu D, et al. miR-34b/c-5p/CXCL10 Axis Induced by RSV Infection Mediates a Mechanism of Airway Hyperresponsive Diseases. Biology 2023; 12.

18. L ong X, et al. IL-17A plays a critical role in RSV infection in children and mice. Virology J 2023; 20: 30.

19. P ischedda S, et al. Role and Diagnostic Performance of Host Epigenome in Respiratory Morbidity after RSV Infection: The EPIRESVi Study. Front Immunol 2022; 13: 875691.

20. Chirkova T, et al. Effect of Infant RSV Infection on Memory T Cell Responses at Age 2-3 Years. Front Immunol 2022; 13: 826666.

21. Backman K, Ollikainen H, Piippo-Savolainen E, et al. Asthma and lung function in adulthood after a viral wheezing episode in early childhood. Clin Experiment Allergy 2018; 48: 138–146.

22. P oulsen A, et al. Long-term consequences of respiratory syncytial virus acute lower respiratory tract infection in early childhood in Guinea-bissau. Pediatric Inf Dis J 2006; 25: 1025–1031.

23. M iller EK, et al. Viral etiologies of infant bronchiolitis, croup and upper respiratory illness during 4 consecutive years. Pediatric Inf Dis J 2013; 32: 950–955.

24. F lorin TA , Plint AC, Zorc JJ. Viral bronchiolitis. Lancet 2017; 389: 211–224.

25. E isenhut M. Extrapulmonary manifestations of severe respiratory syncytial virus infection--a systematic review. Crit Care 2006; 10: R107.

26. E rez DL, et al. Apnea induced by respiratory syncytial virus infection is not associated with viral invasion of the central nervous system. Pediatric Inf Dis J 2014; 33, 880–881.

27. R alston S, Hill V. Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review. J Pediatrics 2009; 155: 728–733.

28. K hiabani K, Amirzade-Iranaq MH. Are saliva and deep throat sputum as reliable as common respiratory specimens for SARS-CoV-2 detection? A systematic review and meta-analysis. Am J Infection Control 2021; 49: 1165–1176.

29. Warren TK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016; 531: 381–385.

30. Jung BK, Choi SH, Lee JH, et al. Performance evaluation of four rapid antigen tests for the detection of Respiratory syncytial virus. J Med Virol 2016; 88: 1720–1724.

31. L eonardi GP, Wilson AM, Dauz M, Zuretti AR. Evaluation of respiratory syncytial virus (RSV) direct antigen detection assays for use in point-of-care testing. J Virol Methods 2015; 213: 131–134.

32. Walsh P, et al. Is the interpretation of rapid antigen testing for respiratory syncytial virus as simple as positive or negative? Emergency medicine journal : EMJ 2014; 31: 153–159.

33. N eopane P, Nypaver J, Shrestha R, Beqaj S. Performance Evaluation of TaqMan SARS-CoV-2, Flu A/B, RSV RT-PCR Multiplex Assay for the Detection of Respiratory Viruses. Inf Drug Resistance 2022; 15: 5411– 5423.

34. Y un J, et al. Evaluation of Three Multiplex Real-time Reverse Transcription PCR Assays for Simultaneous Detection of SARS-CoV-2, Influenza A/B, and Respiratory Syncytial Virus in Nasopharyngeal Swabs. J Korean Med Sci 2021; 36: e328.

35. Quinton M, Geahr M, Gluck L, et al. Evaluation of the respiratory NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage and Alinity m Resp-4-Plex assays. J Clin Virol 2022; 150–151.

36. T rang TP, Whalen M, Hilts-Horeczko A, et al. Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: A single-center retrospective cohort study and review of the literature. Transplant Inf Dis 2018; 20: e12844.

37. Beaird OE, et al. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. Transplant Inf Dis 2016; 18: 210–215.

38. H irsch HH, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Inf Dis 2013; 56: 258–266.

39. M alin JJ, Suarez I, Priesner V, et al. Remdesivir against COVID-19 and Other Viral Diseases. Clin Microbiol Rev 2020; 34.

40. T ian L, et al. Molnupiravir and Its Antiviral Activity Against COVID-19. Front Immunol 2022; 13: 855496.

41. H olman W, et al. Accelerated first-in-human clinical trial of EIDD-2801/MK- 4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2. Trials 2021; 22: 561.

42. F uruta Y, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 2002; 46: 977–981.

43. S kjerven HO, et al. Racemic adrenaline and inhalation strategies in acute bronchiolitis. NEJM 2013; 368: 2286–2293.

44. R alston SL, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics 2014; 134: e1474– 1502.

45. D elgado MF, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nature Med 2009; 15: 34–41.

46. K im HW, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89: 422–434.

47. G riffiths C, Drews SJ, Marchant DJ. Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment. Clin Microbiol Rev 2017; 30: 277–319.

48. M azur NI, et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet. Infectious diseases 2018; 18: e295–e311.